ZORYVE Foam 0.3% Now Available for plaque psoriasis
Inflammatory Dermatoses?
ORYVE® IT
RELIEVE IT
ZORYVE  has the power and
versatility to be your go-to topical.1,2
Not a steroid. No boxed warning
Simple once-daily treatment
ZORYVE (roflumilast) Cream 0.3%, ZORYVE (roflumilast) Cream 0.15%, and ZORYVE (roflumilast) Topical Foam 0.3%
PLAQUE
PSORIASIS

Cream 0.3% for age 6+
Foam 0.3% for age 12+

ATOPIC
DERMATITIS

Cream 0.15% for age 6+

SEBORRHEIC
DERMATITIS

Foam 0.3% for age 9+

Symptoms illustrated. Not actual patients.

Delivers powerful skin
clearance and rapid itch relief,
from head to toe1-3
Safe, long-term disease
control for any skin
and hair type1,2,4-7
#1 prescribed branded topical
across 3 major inflammatory
dermatoses combined8

PLAQUE PSORIASIS: 40% of patients achieved IGA Success with ZORYVE cream 0.3% at Week 8 vs 7% with vehicle. 69% of patients achieved WI-NRS Success at Week 8 with ZORYVE cream 0.3% vs 31% with vehicle. 63% of patients achieved S-IGA Success with ZORYVE foam at Week 8 vs 21% with vehicle. 42% of patients achieved B-IGA Success with ZORYVE foam at Week 8 vs 15% with vehicle. In ARRECTOR, 65% of patients achieved SI-NRS Success at Week 8 with ZORYVE foam vs 30% with vehicle, 63% of patients experienced WI-NRS Success at Week 8 with ZORYVE foam vs 30% vehicle.1,2,8-10

ATOPIC DERMATITIS: 31% of patients achieved vIGA-AD Success at Week 4 with ZORYVE cream 0.15% vs 14% with vehicle. 32% of patients achieved WI-NRS Success at Week 4 with ZORYVE cream 0.15% vs 17% with vehicle.1,11,12

SEBORRHEIC DERMATITIS: 77% of patients achieved IGA Success with ZORYVE foam at Week 8 vs 53% with vehicle. In STRATUM, 63% of patients achieved WI-NRS Success at Week 8 with ZORYVE foam vs 41% with vehicle.2,8,13

See the study design below.